Checkmate Therapeutics was founded in 2019 based on discoveries made by its scientific founders at Yonsei University in Seoul, South Korea. Our mission is to discover, develop and deliver innovative therapeutics for patients suffering from cancer and other incurable diseases: CX001, the first small-molecule compound in our pipeline, inhibits the enzymatic activity of a target protein associated with tumor metastasis, therapy resistance, and immune evasion. We are now actively expanding our pipeline through in-house research and development efforts and through acquisition of external assets from academia and industry, most of which are primarily in the pre-IND stage of drug development.

Our strategy is to create value by advancing pipeline programs through preclinical and early stage clinical development, ranging from lead candidate selection to proof of concept, before licensing out to big pharma companies.